
price close busi juli
biomed devic servic
start execut still earli
bottom line maintain hold rate post result overal
result definit show encourag pocket perform continu apac
strength particular remain cautiou time acceler top-lin growth
unlock sharehold valu think guidanc
appropri conserv xfx sale growth commentari season
time new product launch control full commerci releas
increasingli weight second half earli believ
reflect time invest requir turnaround play stick
hold
sum current valuat ep estim friday close
though note stock friday surpris long-term
investor start opportunist build posit rest
year particularli given manag provid enough forward inform start
piec togeth mosaic bottom line stori get better
strategy/cultur chang begin make impact month new
manag helm howev one quarter trend make look
complet addit dilig puts/tak rosa underli implant
busi turn materi posit
top line post revenu compar cg/street estim
apac continu strong momentum xfx growth
continu benefit weight legaci zimmer product less
affect suppli issu
manufactur qualiti call manag reiter confid
progress made remedi effort state remain track
two-year turnaround plan set compani resum market rate
top-lin growth oper focu begin shift
simpli stabil suppli drive effici improv cost structur
addit manag note dramat cultur chang insid
compani continu optim talent structur state
recent team survey show respond felt either confid
confid zimmer strategi futur growth said high-end
guidanc unchang posit develop oper
side alreadi anticip point continu think qualiti issu
fulli resolv eventu remain cautiou regard near-term leverag
pipelin updat manag reiter expect pipelin product play
import part compani return sustain revenu earn growth
manag note earli focu rosa knee busi
knee capit sale similar small number unit deliv remind
rosa knee/spine/brain sale flow associ busi somewhat
cloud metric underli perform feel larg posit
result look complet dilig come month get better insight
capit placement underli util continu view broader
pipelin posit howev expect take least
product materi impact top-lin growth
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
zimmer report sale slightli estim
street revenu support continu strength asia
pacif region expect off-set weak emea
expect addit gross margin
expect oper margin slightli estim
manag continu invest cog leverag commerci
product develop initi zimmer report adjust ep line
estim consensu
figur result vs estim consensu
low-end revenu guidanc rais slightli flat
guidanc call top-lin growth rang flat inclus
neg bp fx impact impli constant currenc sale growth
y/i pro forma ep expect guid rang
compar cg/consensu adjust oper margin
guid rang line estim
compani adjust tax rate expect line estim
hold unchang target price juli
biomed devic servic
overal performanceactualcg estimatebeat/miss beat/miss consensusbeat/missnet good gross pro-forma gross pro-forma oper net revenu productactualcg estimatebeat/miss beat/miss growthnet revenu geographyactualcg estimatebeat/miss beat/miss growthnet number us million zimmer biomet hold
chang estim
made follow chang estim
figur summari chang estim
broad large-cap med-tech group current trade mean price-to-earnings multipl
valu zimmer discount large-cap med-tech group given
uncertainti surround remedi suppli issu impact revenu
margin sum adjust pt base price-to-earnings multipl
appli pro-forma ep
hold unchang target price juli
biomed devic servic
except ep newold newold newold revenu gross operatin ebitda net zimmer biomet hold
figur matrix discount rate impli share price target
zimmer biomet
zimmer world-wide leader design develop manufactur market
reconstruct spinal implant trauma relat orthoped surgic product
hold unchang target price juli
biomed devic servic
comp pe multipl price metric use price-to-earnings valuat analysisbroad large-cap medic devic price-to-earnings multipl adjust pro-forma figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
hold unchang target price juli
biomed devic servic
zimmer biomet incom statementcanaccord genuiti kyle except per share good devic gener asset op incom chg chg amort stk incom minor incom ep ep ep chg share gener oper rate adjust growth ep ex growth ep ex compani document canaccord genuiti estim figur pro forma revenu build
hold unchang target price juli
biomed devic servic
zimmer biomet revenu buildcanaccord genuiti kyle euro yen fx impact impact fx growth growth zimmer biomet hold
